What Happened?
Cambridge, MA-based Potenza Therapeutics Appointed Daniel Hicklin as Chief Executive Officer
About the Company
Potenza Therapeutics is a biotechnology company focused on building a diverse portfolio of oncology programs that utilize the body`s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms. Our programs are built upon novel biological insights into the tumor microenvironment and mechanisms by which cancer cells evade detection and destruction by the immune system. Potenza Therapeutics was founded in 2014 and is located in Cambridge, MA.
About the Person
Daniel Hicklin brings to Potenza over 25 years of biopharmaceutical research and operations experience with particular expertise in oncology drug development. Dr. Hicklin co-founded Potenza in 2014 and is the company`s President and CEO. He has served as a Managing Director at the life sciences venture capital investment firm MPM Capital since 2014 and is also a board member of Tizona Therapeutics and Harpoon Therapeutics. Previously, Dr. Hicklin served as President and Chief Scientific Officer of CoStim Pharmaceuticals, which was acquired by Novartis in 2014. From 2007 to 2013, he held several positions at Merck Research Laboratories and the former Schering-Plough Research Institute, most recently leading Biologics Strategy for Oncology and overseeing immuno-oncology discovery research at Merck Research Laboratories in Boston. Dr. Hicklin began his career at ImClone Systems where he held several positions of increasing responsibility from 1987 - 2007, most recently serving as Vice President of Experimental Therapeutics. Dr. Hicklin`s team at ImClone supported the development and FDA approval of the cancer treatment ERBITUX® (Cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), necitumumab, and other cancer therapies that were acquired by Eli Lilly in 2008. Dr. Hicklin has co-authored over 200 peer-reviewed publications and is an inventor on numerous issued and pending patents. Dr. Hicklin received his Master`s and PhD in Microbiology & Immunology from New York Medical College and earned his BS from the University of Iowa.
Info Source
Press Release
Short Profile